James F Hulvat

age ~48

from Cincinnati, OH

Get Report
Also known as:
  • James M Hulvat
  • Jason F Hulvat
  • James T
Related to:
Connected to:

James Hulvat Phones & Addresses

  • Cincinnati, OH
  • Bend, OR
  • 180 Wakewood Dr, Kalispell, MT 59901 • 4062576065
  • 21 Chestnut St, Chicago, IL 60610 • 3126430804
  • 3696 Granger Rd, Akron, OH 44333 • 3306681992
  • Mountain View, CA
  • Ithaca, NY
  • Sunnyvale, CA
  • 180 Wakewood Dr, Kalispell, MT 59901

Work

  • Company:
    Thermo fisher scientific
    Aug 2019
  • Position:
    Senior manager, project management

Education

  • Degree:
    Doctorates, Doctor of Philosophy
  • School / High School:
    Northwestern University
    1999 to 2004
  • Specialities:
    Materials Science, Engineering

Skills

Nanotechnology • Chemistry • Biotechnology • R&D • Materials Science • Spectroscopy • Technology Transfer • Biomaterials • Nanomaterials • Scanning Electron Microscopy • Hplc • Powder X Ray Diffraction • Uv/Vis • Microscopy • Tem • Thin Films • Tissue Engineering • Optical Microscopy • Xps • Surface Chemistry • Polymer Characterization • Organic Chemistry • Electron Microscopy • Biomedical Engineering • Mass Spectrometry • Afm • Fluorescence • Electrochemistry • Polymers • Nanofabrication • Pre Clinical Studies • Experimental Design • Analytical Chemistry • Drug Delivery • Spray Drying • Amorphous Drug Dispersions • Entrepreneurship • Grant Writing • Technical Writing • Drug Development • Glp • Fda Gmp • Liquid Crystals • Polarized Light Microscopy • Peptides • Solid Phase Synthesis • Nmr • Toxicology • Intellectual Property • Ftir

Industries

Pharmaceuticals

Resumes

James Hulvat Photo 1

Senior Manager, Project Management

view source
Location:
Bend, OR
Industry:
Pharmaceuticals
Work:
Thermo Fisher Scientific
Senior Manager, Project Management
Thermo Fisher Scientific
Manager, Project Management
Patheon
Manager of Applied Technologies
Agere Pharmaceuticals, Inc. Jul 2014 - Mar 2015
Manager of Applied Technologies
Arrowhead Pharmaceuticals, Inc. Nov 2010 - Feb 2014
Director, Research and Development
Education:
Northwestern University 1999 - 2004
Doctorates, Doctor of Philosophy, Materials Science, Engineering Cornell University 1995 - 1999
Bachelors, Bachelor of Science, Materials Science, Engineering
Skills:
Nanotechnology
Chemistry
Biotechnology
R&D
Materials Science
Spectroscopy
Technology Transfer
Biomaterials
Nanomaterials
Scanning Electron Microscopy
Hplc
Powder X Ray Diffraction
Uv/Vis
Microscopy
Tem
Thin Films
Tissue Engineering
Optical Microscopy
Xps
Surface Chemistry
Polymer Characterization
Organic Chemistry
Electron Microscopy
Biomedical Engineering
Mass Spectrometry
Afm
Fluorescence
Electrochemistry
Polymers
Nanofabrication
Pre Clinical Studies
Experimental Design
Analytical Chemistry
Drug Delivery
Spray Drying
Amorphous Drug Dispersions
Entrepreneurship
Grant Writing
Technical Writing
Drug Development
Glp
Fda Gmp
Liquid Crystals
Polarized Light Microscopy
Peptides
Solid Phase Synthesis
Nmr
Toxicology
Intellectual Property
Ftir

Us Patents

  • Oligo(P-Phenylene Vinylene) Amphiphiles And Methods For Self-Assembly

    view source
  • US Patent:
    7371887, May 13, 2008
  • Filed:
    Dec 6, 2004
  • Appl. No.:
    11/005558
  • Inventors:
    Samuel I. Stupp - Chicago IL, US
    James F. Hulvat - Chicago IL, US
    Marina Sofos - Evanston IL, US
    Keisuke Tajima - Evanston IL, US
  • Assignee:
    Northwestern University - Evanston IL
  • International Classification:
    C07C 69/76
    C07C 217/54
    C07C 43/215
    H01L 21/00
  • US Classification:
    560 57, 560 64, 564156, 564171, 564181, 564183, 564186, 564283, 564285, 564286, 564287, 564288, 564290, 568609, 568640, 568646, 2522996
  • Abstract:
    Amphiphilic oligo(p-phenylene vinylene) compounds and methods of use en route to self-assembled composites and device fabrication.

  • Angiogenic Heparin-Binding Epitopes, Peptide Amphiphiles, Self-Assembled Compositions And Related Methods Of Use

    view source
  • US Patent:
    7851445, Dec 14, 2010
  • Filed:
    Mar 6, 2006
  • Appl. No.:
    11/368582
  • Inventors:
    Samuel I. Stupp - Chicago IL, US
    Kanya Rajangam - Wilmette IL, US
    James F. Hulvat - Chicago IL, US
  • Assignee:
    Northwestern University - Evanston IL
  • International Classification:
    A61K 38/10
  • US Classification:
    514 14, 530326
  • Abstract:
    Peptide amphiphiles and related compositions comprising sulfated polysaccharides, such as but not limited to sulfated glycosaminoglycans, and methods of use relating to the encapsulation and/or controlled release of angiogenic growth factor(s).

  • Peptide Amphiphiles Having Improved Solubility And Methods Of Using Same

    view source
  • US Patent:
    8076295, Dec 13, 2011
  • Filed:
    Apr 16, 2008
  • Appl. No.:
    12/104407
  • Inventors:
    James F. Hulvat - Chicago IL, US
    Mustafa O. Guler - Chicago IL, US
  • Assignee:
    Nanotope, Inc. - Skokie IL
  • International Classification:
    A61K 38/10
    C07K 1/113
    C07K 7/08
    C12N 11/08
  • US Classification:
    514 177, 435397, 514 191, 514 215, 530327, 530334, 530345
  • Abstract:
    Disclosed herein are novel peptide amphiphile molecules and compositions discovered to possess improved solubility in aqueous buffers which, in turn, facilitates purification required for pharmaceutical applications, particularly for in vivo administration to human patients. In addition, gels of such peptide amphiphile compositions are shown herein to possess unexpectedly superior gelation kinetics and rheological properties, including an increased mechanical stiffness, which better mimics the mechanical properties of natural central nervous system tissues.

  • Liquid Crystal-Templated Conducting Organic Polymers

    view source
  • US Patent:
    20030087533, May 8, 2003
  • Filed:
    Oct 17, 2002
  • Appl. No.:
    10/272707
  • Inventors:
    Samuel Stupp - Chicago IL, US
    James Hulvat - Chicago IL, US
  • International Classification:
    H01L021/302
  • US Classification:
    438/745000
  • Abstract:
    A method of preparing a conductive polymeric film, includes providing a liquid crystal phase comprising a plurality of hydrophobic cores, the phase on a substrate, introducing a hydrophobic component to the phase, the component a conductive polymer precursor, and applying an electric potential across the liquid crystal phase, the potential sufficient to polymerize the said precursor.

  • Adipose Tissue Targeted Peptides

    view source
  • US Patent:
    20130237476, Sep 12, 2013
  • Filed:
    Mar 5, 2013
  • Appl. No.:
    13/785566
  • Inventors:
    James F. HULVAT - Kalispell MT, US
  • Assignee:
    ABLARIS THERAPEUTICS INC. - Pasadena CA
  • International Classification:
    C07K 14/00
    C07K 7/02
  • US Classification:
    514 48, 530324, 530323, 514 213, 514 215
  • Abstract:
    The application provides synthetic peptide conjugates capable of targeting and causing ablation of adipose tissue in mammal comprising at least one targeting peptide and at least one therapeutic peptide. The synthetic peptide conjugates are envisaged to have decreased physiological toxicity and/or enhanced in situ cytotoxicity compared to the peptide CKGGRAKDC-GG-(KLAKLAKKLAKLAK) (SEQ ID NO: 2).

  • Pharmaceutical Compositions For The Treatment Of Hbv

    view source
  • US Patent:
    20220241208, Aug 4, 2022
  • Filed:
    May 22, 2020
  • Appl. No.:
    17/613670
  • Inventors:
    - San Francisco CA, US
    George Koan WONG - Belle Mead NJ, US
    Kirk HENNE - Belmont CA, US
    James Francis HULVAT - Cincinnati OH, US
    Sanjay KONAGURTHU - Bend OR, US
    Ian Scott MCINTOSH - Bend OR, US
    Matthew David WESSEL - Sisters OR, US
    Thomas REYNOLDS - Bend OR, US
    Richard J. COLONNO - San Francisco CA, US
    Uri A. LOPATIN - San Francisco CA, US
  • International Classification:
    A61K 9/20
    A61K 9/10
    A61K 31/554
    A61K 47/32
    A61K 47/38
    A61K 9/16
    A61K 47/26
    A61K 47/02
    A61K 47/14
    A61K 45/06
    A61P 31/20
  • Abstract:
    The present disclosure provides, in part, pharmaceutical compositions that comprise a spray dried dispersion which contains the disclosed compound, and optionally, pharmaceutical excipients. The pharmaceutical compositions of the disclosure may be used in the treatment of Hepatitis B (HBV).

  • Novel Formulations Of A Bruton's Tyrosine Kinase Inhibitor

    view source
  • US Patent:
    20190282578, Sep 19, 2019
  • Filed:
    Oct 19, 2018
  • Appl. No.:
    16/165895
  • Inventors:
    - Sunnyvale CA, US
    Ching Wah Chong - Fremont CA, US
    Robert Kuehl - San Francisco CA, US
    Cassandra Shu - Belmont CA, US
    Pearl Shwe-Cho Tay - Union City CA, US
    James Francis Hulvat - Bend OR, US
    Alexander Jacob McVey - Bend OR, US
    Ryan Mitchell Minikis - Bend OR, US
  • International Classification:
    A61K 31/519
    A61K 9/20
    A61K 9/16
    A61K 9/14
    A61K 9/10
    A61K 47/26
    A61K 47/12
    A61K 47/02
    A61K 47/38
  • Abstract:
    Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  • Novel Formulations Of A Bruton's Tyrosine Kinase Inhibitor

    view source
  • US Patent:
    20180028537, Feb 1, 2018
  • Filed:
    Mar 17, 2017
  • Appl. No.:
    15/462444
  • Inventors:
    - Sunnyvale CA, US
    Ching Wah Chong - Fremont CA, US
    Robert Kuehl - San Francisco CA, US
    Cassandra Shu - Belmont CA, US
    Pearl Shwe-Cho Tay - Union City CA, US
    James Francis Hulvat - Bend OR, US
    Alexander Jacob McVey - Bend OR, US
    Ryan Mitchell Minikis - Bend OR, US
  • International Classification:
    A61K 31/519
    A61K 47/26
    A61K 47/02
    A61K 9/10
    A61K 9/20
    A61K 9/16
    A61K 47/38
    A61K 47/12
  • Abstract:
    Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Facebook

James Hulvat Photo 2

James Hulvat

view source

News

Drug Slims Down Obese Monkeys by Killing Fat Cells

view source
  • James Hulvat, head of research and development for Ablaris Therapeutics, said the decision to test the agent first in obese prostate-cancer patients reflected in part the interests M.D. Anderson, which is paying for the initial study, and the agent's potential for demonstrating an important benefit
  • Date: Nov 09, 2011
  • Category: Health
  • Source: Google
Get Report for James F Hulvat from Cincinnati, OH, age ~48
Control profile